First report of c. 1499G>C mutation in a 6-month-child with cystic fibrosis

Abbas Sahami1, Nourkhoda Sadeghifard2, Alireza Monsef3

  • 1Department of Medical Genetic and Embryology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.

Insights

This case report details the first identification of the novel c.1499G>C mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in a young Iranian girl diagnosed with cystic fibrosis (CF). Further research into this mutation is recommended.

Area of Science:

  • Genetics
  • Pediatrics
  • Medical Case Reports

Background:

  • Over 1800 mutations have been identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
  • Cystic Fibrosis (CF) is a genetic disorder affecting multiple organs.
  • Early diagnosis and genetic analysis are crucial for CF management.

Observation:

  • A 6-month-old girl presented with weakness and meconium ileus, indicative of CF.
  • Clinical signs included dark skin and bronchiectasis.
  • Elevated sweat chloride (130-135 mmol/L) and sodium (125-128 mmol/L) levels confirmed CF diagnosis.

Findings:

  • Genetic analysis revealed two CFTR mutations: p.F508del (ΔF508) and the novel c.1499G>C (cd500).
  • The c.1499G>C (cd500) mutation is reported globally for the first time.
  • This represents a significant addition to the known pathogenic variants of the CFTR gene.

Implications:

  • This discovery expands the mutational landscape of cystic fibrosis.
  • Further investigation of the c.1499G>C mutation is crucial for understanding its clinical impact.
  • This finding underscores the importance of comprehensive genetic screening in CF diagnosis.